Oxford vaccine effective but questions above 55: report

Oxford-Astra data will be examined worldwide, counting vaccines in many countries.

The day Britain began vaccinating its population with the Kovid-19 shot developed by Germany’s BioNtech SE and Pfizer Inc. of the US, a study by a peer of the UK homegrown vaccine left some key questions.

According to the results published in The Lancet on Tuesday, a vaccine developed by Oxford University and AstraZeneca plc is safe and effective, more analysis will be needed to see how well it works in people over 55, epidemic-high. In people at risk. .

Because older adults were recruited for later studies than at puberty, “they had less time for cases in those age groups and for us to be able to measure an efficacy signal,” Andrew Pollard, Oxford Chief investigator of said. testing. “The evidence we have so far on the immune response suggests that it is likely to have the same level of protection throughout the ages.”

Uk rollout

The Pfizer-BioNTech shot, which was approved in the UK last week, could be approved this week in the US and the European Union by the end of the year as governments race to clear up a dispute that has raised more than 1.5 million Life has destroyed and economies. The Astra-Oxford shot is less effective than that vaccine and another one from Modern Inc., which shows 95% efficacy in each trial, but is expected to be cheaper and easier to deploy.

The Lancet Report provides the first peer-reviewed data from any leading vaccine.


Initial figures for Astra and Oxford looked positive last month, but concerns were raised about how much protection the shot would get after two different results from the two dodging regimes after the trial. The partners stated that their vaccine was 90% effective when given one half-dose before a full-dose booster, and two full doses showed an efficacy of 62%.

It later emerged that the low dose was the result of a manufacturing mistake and was only tested in a small group. Astra CEO Pascal Soriot said in an interview last month that the company would set up an additional, perhaps global, test to verify 90% of the results. On Tuesday, the company said it was still deciding whether to conduct additional studies, while Pollard said there were currently no plans for an additional UK trial in Oxford. A separate study is already underway in the US

no hurry

According to Bloomberg Intelligence Analyst Sam Fazley, the efficacy rate may be high for the vaccine to be approved, given the variability in the various subgroups and the lack of data for older people that regulators must allow.

“I’ll wait until at least the American trial, which is much more tightly controlled in terms of dosage and interval between doses, before the vaccine is approved,” Fazli said.

Results were reviewed based on advanced trials of 11,636 people in the UK and Brazil, with 131 participants contracted Kovid-19. According to data from The Lancet, there were 30 in the group who received 101 in the vaccine and control arm, with an efficacy rate of 70%.


The vast majority of 175 serious adverse events were thought to be unrelated to the Kovid-19 or control shots, a case of the neurological disorder transverse myelitis may be associated with the shot, the paper said.

Astra shares rose 0.8% in London on Tuesday.

study more

Trials are needed to advance the findings and to investigate efficacy in older adults, Maria Deloria Knoll and Chizoba Vanodi of the Johns Hopkins Bloomberg School of Public Health wrote in an article with the data.

The authors noted “limitations” with the results, which included less than 4% of participants who were over 70 years old, as well as found that no participants over 55 years of age had a mixed-dose diet. met. Nevertheless, he said the expected low price of the vaccine holds promise for low and middle income countries.

“Despite the excellent questions and challenges in delivering these vaccines, it is hard not to get excited about these findings and the existence of three safe and effective Kovid-19 vaccines,” he wrote.

While the real efficacy of the Astra-Oxford jab and regulatory approval in the UK and EU of additional study plans are not expected, Sorot said that green light is possible in the UK with a year-end. There would be no US approval until 2021, after the trial was halted for about seven weeks following a suspected transverse myelitis incident in a UK study. The British trial resumed in less than a week.

Oxford-Astra data will be scrutinized worldwide, with many countries counting the vaccine to protect their populations. It will take a fraction of the price set by Pfizer and BioNTech and shot from Modern. Even for Pfizer’s shot, the Astra vaccine should be easier to deploy with storage temperatures between two and eight degrees Celsius than the minus 70.

(Except for the headline, this story has not been edited by NDTV employees and published from a syndicated feed.)



Please enter your comment!
Please enter your name here